Santen Pharmaceutical Co., Ltd. (TYO:4536)

Japan flag Japan · Delayed Price · Currency is JPY
1,650.50
+3.00 (0.18%)
Apr 28, 2026, 3:30 PM JST
17.39%
Market Cap 530.93B
Revenue (ttm) 287.99B
Net Income (ttm) 30.60B
Shares Out 321.68M
EPS (ttm) 91.84
PE Ratio 17.97
Forward PE 15.27
Dividend 38.00 (2.31%)
Ex-Dividend Date Mar 30, 2026
Volume 656,000
Average Volume 883,005
Open 1,651.00
Previous Close 1,647.50
Day's Range 1,631.00 - 1,652.00
52-Week Range 1,397.00 - 1,939.00
Beta 0.28
RSI 34.55
Earnings Date May 12, 2026

About Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd. engages in the research and development, manufacturing, and marketing of pharmaceuticals and medical devices in Japan, China, Asia, Europe, the Middle East, Africa, and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2α derivative and a beta-adrenergic receptor blocker for the treatment of glaucoma and ocular hypertension; ciclosporin, an ophthalmic emulsion for the treatment of vernal keratoconjunctivitis, as well as latanoprost, an ophthalmic emulsion of a prostaglan... [Read more]

Sector Healthcare
Founded 1890
Employees 3,849
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4536
Full Company Profile

Financial Performance

In fiscal year 2025, Santen Pharmaceutical's revenue was 300.00 billion, a decrease of -0.65% compared to the previous year's 301.97 billion. Earnings were 36.25 billion, an increase of 36.09%.

Financial Statements

News

There is no news available yet.